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ORIGINAL RESEARCH
Renin–Angiotensin System Blockers 
and Adverse Outcomes of Influenza and 
Pneumonia: A Danish Cohort Study
Christian Fynbo Christiansen , MD, PhD; Uffe Heide-Jørgensen, MSc, PhD; Thomas Bøjer Rasmussen , MSc; 
Jacob Bodilsen, MD; Ole Schmeltz Søgaard, MD, PhD; Michael Maeng, MD, PhD; Simon Tilma Vistisen, MSc, PhD; 
Morten Schmidt, MD, PhD; Anton Pottegård, MSc, PhD, DMSc; Lars Christian Lund , MD; Mette Reilev , MD, PhD; 
Jesper Hallas, MD, DMSc; Nanna Borup Johansen , MD, PhD; Nikolai Constantin Brun, MD, PhD;  
Henrik Toft Sørensen, MD, PhD, DMSc; Reimar Wernich Thomsen , MD, PhD
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) may worsen the 
prognosis of coronavirus disease 2019, but any association could be confounded by the cardiometabolic conditions indicating 
ACE-I/ARB use. We therefore examined the impact of ACE-Is/ARBs on respiratory tract infection outcomes.
METHODS AND RESULTS: This cohort study included all adult patients hospitalized with influenza or pneumonia from 2005 to 
2018 in Denmark using population-based medical databases. Thirty-day mortality and risk of admission to the intensive care 
unit in ACE-Is/ARBs users was compared with nonusers and with users of calcium channel blockers. We used propensity 
scores to handle confounding and computed propensity score-weighted risks, risk differences (RDs), and risk ratios (RRs). Of 
568 019 patients hospitalized with influenza or pneumonia, 100 278 were ACE-I/ARB users and 37 961 were users of calcium 
channel blockers. In propensity score-weighted analyses, ACE-I/ARB users had marginally lower 30-day mortality than users 
of calcium channel blockers (13.9% versus 14.5%; RD, −0.6%; 95% CI, −1.0 to −0.1; RR, 0.96; 95% CI, 0.93–0.99), and a lower 
risk of admission to the intensive care unit (8.0% versus 9.6%; RD, −1.6%; 95% CI, −2.0 to −1.2; RR, 0.83; 95% CI, 0.80–0.87). 
Compared with nonusers, current ACE-I/ARB users had lower mortality (RD, −2.4%; 95% CI, −2.8 to −2.0; RR, 0.85; 95% CI, 
0.83–0.87), but similar risk of admission to the intensive care unit (RD, 0.4%; 95% CI, 0.0–0.7; RR, 1.04; 95% CI, 1.00–1.09).
CONCLUSIONS: Among patients with influenza or pneumonia, ACE-I/ARB users had no increased risk of admission to the inten-
sive care unit and slightly reduced mortality after controlling for confounding.
Key Words: angiotensin receptor blockers ■ angiotensin-converting enzyme inhibitor ■ cohort study ■ infectious disease  
■ intensive care unit
Use of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) may increase the risk of developing severe or fatal 
coronavirus disease 2019 (COVID-19) by upregulating 
expression of the ACE2 enzyme, which is known to 
facilitate severe acute respiratory syndrome-corona-
virus 2 entry into cells.1–5 Case series of hospitalized 
patients with severe and fatal COVID-19 from China,6–8 
Italy,9 and the United States10,11 have reported a high 
prevalence (≈30%–40%) of hypertension, cardiovas-
cular conditions, and diabetes mellitus—conditions 
often treated with ACE-Is/ARBs.12 Data are currently 
lacking to clarify whether treatment of these coexist-
ing conditions, including ACE-I/ARB use, contributed 
to the observed adverse health outcomes, or if pa-
tients had worse outcomes simply because they were 
Correspondence to: Christian Fynbo Christiansen, MD, PhD, Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45,  
DK-8200 Aarhus N, Denmark. E-mail: cfc@clin.au.dk
Supplementary Material for this article is available at https://www.ahajo urnals.org/doi/suppl/ 10.1161/JAHA.120.017297
For Sources of Funding and Disclosures, see page 14.
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.  This is an open access article under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use 
is non-commercial and no modifications or adaptations are made. 
JAHA is available at: www.ahajournals.org/journal/jaha
D
ow
nloaded from
 http://ahajournals.org by on D
ecem
ber 11, 2020
J Am Heart Assoc. 2020;9:e017297. DOI: 10.1161/JAHA.120.017297 2
Christiansen et al RAS Blockers and Outcome of Influenza/Pneumonia
older and suffered from cardiometabolic conditions (ie, 
confounding by indication).2,12–15 A few studies have 
suggested an association between ACE-I and ARB 
use and decreased mortality from bacterial pneumo-
nia.16–18 Although preadmission ACE-I use has been 
associated with increased mortality in patients hospi-
talized for viral diseases,19 two small studies of patients 
with COVID-19 do not indicate any increased mortality 
in inpatient users of ACE-Is/ARBs.20,21 Most of the ex-
isting studies had limitations: They did not have ACE-I/
ARB use as their main exposure, had mixed pneumo-
nia risk and outcome, were biased by studying in-hos-
pital medication after study inclusion, or were small 
with imprecise estimates.
Major institutions and societies have called for fur-
ther research and issued warnings against ACE-I/ARB 
discontinuation in patients with COVID-19,21 as drug 
discontinuation may worsen underlying cardiomet-
abolic conditions.22 Thus, there is an urgent need to 
clarify the impact of ACE-Is/ARBs on outcomes of 
lower respiratory tract infections. We report here on a 
large population-based cohort study investigating the 
impact of ACE-I/ARB use on intensive care unit (ICU) 
admission and death following hospitalization for influ-
enza or pneumonia, while controlling for potential con-
founding by indication by using active antihypertensive 
drug comparators.
METHODS
The study was approved by the Danish Data Protection 
Agency (record number 2014-54-0922) through regis-
tration at Aarhus University (record number KEA-2017-
36/812). Ethics approval and informed consent are not 
required for registry-based observational studies in 
Denmark.
Study Design and Setting
This nationwide cohort study included all patients diag-
nosed with influenza or pneumonia in Danish hospitals 
from January 1, 2005 through September 30, 2018, 
with follow-up to October 31, 2018. The study design 
is summarized in Figure S1. Denmark has a tax-sup-
ported healthcare system providing equal access to 
all acute care, including hospital care for pneumonia.23 
All Danish residents receive a personal identity number 
at birth or upon immigration, which allows individual-
level linkage among medical databases and registries. 
The Danish Civil Registration System is a population 
registry that contains data updated daily on the vital 
status (deceased or alive) and residence of all Danish 
residents.24 (Because of the sensitive nature of the 
data collected for this study, requests to access the 
databases used in this study from researchers at au-
thorized institutions may be sent to the Danish Health 
Data Authority by e-mail to forskerservice@sundheds-
data.dk.)
Influenza and Pneumonia
The study examined all hospitalizations by adult mem-
bers (aged ≥18 years) of the study cohort who had ei-
ther a primary or secondary diagnosis of influenza or 
pneumonia using the Danish National Patient Registry 
data (Figure  1).25 Among other variables, the patient 
registry includes data on the dates of hospital con-
tact/admission and discharge, primary and second-
ary diagnoses, and procedure codes. Influenza or 
pneumonia contacts were not included if preceded by 
an influenza or pneumonia diagnosis within the prior 
3 months, to avoid inclusion of readmissions relating 
to the same disease episode. Finally, we predefined 
subgroups diagnosed with influenza or diagnosed with 
pneumonia with bacterial or unspecified pathogen 
(codes provided in Table S1).
Outcomes
The primary study outcomes were death within 
30  days after hospital admission and ICU admis-
sions during the index hospitalization, including 
transferals between departments and hospitals after 
the diagnosis of influenza or pneumonia. Secondary 
outcomes included organ-supportive treatment 
during ICU admission with mechanical ventilation, 
CLINICAL PERSPECTIVE
What Is New?
• In this large cohort study of more than 500 000 
patients hospitalized with influenza or pneumo-
nia, users of angiotensin-converting enzyme in-
hibitors or angiotensin receptor blockers had no 
increased risk of intensive care unit admission 
and a slightly reduced mortality after controlling 
for confounding.
What Are the Clinical Implications?
• Our data support the current recommendations 
to avoid discontinuation of angiotensin-convert-
ing enzyme inhibitors and angiotensin receptor 
blockers during the current coronavirus disease 
2019 pandemic, unless future evidence contra-
dicts our findings.
Nonstandard Abbreviations and Acronyms
COVID-19 coronavirus disease 2019
PS propensity score
RD risk difference
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noninvasive ventilation, and inotropes/vasopressors. 
Finally, dialysis-treated acute kidney injury was de-
fined as treatment with acute renal replacement ther-
apy in patients with no history of previous dialysis for 
chronic kidney disease. Outcomes were ascertained 
using population registry data for all-cause death, 
and diagnosis and procedure data from the patient 
registry for all other outcomes.24–26
Exposures
Data on all filled prescriptions for cardiovascular 
medications were obtained from the Danish National 
Prescription Registry.27 Our main exposure of interest 
was current use of either ACE-Is or ARBs. We defined 
current use as a filled prescription within 90 days be-
fore the hospital contact for influenza or pneumonia; 
most prescriptions for ACE-Is/ARBs filled in Danish 
pharmacies are for a 3-month supply.
In our main analyses, current ACE-I/ARB users 
were compared with current calcium channel blocker 
(CCB) use and with nonusers of ACE-Is/ARBs (no pre-
scription 365 days before index date). We chose CCBs 
as the active comparator drug because CCBs are also 
a first-line treatment for hypertension, and have no 
known pharmacological effects on the renin–angio-
tensin–aldosterone system, in contrast to β blockers 
and thiazides. Current users of both ACE-Is/ARBs and 
CCBs were excluded from the head-to-head compari-
son of these drugs.
In our second analysis, we examined the out-
comes of former ACE-I/ARB users (prescription filled 
91 to 365 days before index date) versus nonusers 
to address potential uncontrolled confounding by 
indication.
Potential Confounders
We included a range of variables potentially associated 
both with cardiovascular drug use and with the out-
comes of interest. Age and sex were obtained from the 
population registry.24 We included information on coex-
isting conditions requiring inpatient or outpatient hospi-
tal contact within 10 years before the index admission 
from the patient registry (see Table 1 and Table S1 for 
included codes).25 Prescriptions for important concur-
rent medications filled within 90 days before admission 
were also included.27 Finally, as socioeconomic mark-
ers, we included data on marital status and on urban 
versus rural residence.
Statistical Analysis
Patient characteristics were tabulated according to 
exposure groups before and after propensity score- 
(PS-) weighting. The PS, which measures the proba-
bility of being exposed, was estimated using a logistic 
Figure 1. Patient flow diagram.
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and CCB, calcium channel blocker.
Hospital-diagnosed influenza or pneumonia 
Jan 1, 2005 – Sep 30, 2018
N=641 087
Adults aged ≥18 years
N=568 660
Final study population of adults with influenza or 
pneumonia
N=568 019
Current 
ACE-I/ARB use
N=133 433 
Current 
CCB use
N=71 116 
Children <18 years
N=72 427
Not living in Denmark/no follow-up data
N=641
Current ACE-I/ARB use 
without CCB
N=100 278
Current CCB use 
without ACE-I/ARB
N=37 961
Combination of ACE-I/ARB and CCB
N=33 155
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Table 1. Characteristics of Current Users of ACE-Is or ARBs and CCBs Admitted With Influenza or Pneumonia, Overall and 
After PS-Weighting
Overall Cohort PS-Weighted Cohort
Current ACE-I/ 
ARB Use, 
N (%)
Current  
CCB Use, 
N (%) SD
Current ACE-I/ 
ARB Use, 
N (%)
Current  
CCB Use*, 
N (%) SD
No. of patients 100 278 (72.5) 37 961 (27.5) 100 278 (50.2) 99 625 (49.8)
Age, median (Q1–Q3), y 76.9 (68.5–83.9) 78.8 (70.2–85.8) 0.21 76.9 (68.5–83.9) 77.5 (69.1–84.3) 0.07
Male 53 833 (53.7) 18 500 (48.7) 0.14 53 833 (53.7) 51 740 (51.9) 0.05
Coexisting conditions (within prior 10 y)
Hospital-diagnosed 
hypertension
51 716 (51.6) 21 587 (56.9) 0.15 51 716 (51.6) 54 522 (54.7) 0.09
Previous myocardial 
infarction
13 449 (13.4) 3335 (8.8) 0.21 13 449 (13.4) 13 416 (13.5) 0.00
Diagnosis of stable angina 
pectoris
18 861 (18.8) 6440 (17.0) 0.07 18 861 (18.8) 18 714 (18.8) 0.00
Heart failure 26 518 (26.4) 4330 (11.4) 0.55 26 518 (26.4) 26 546 (26.6) 0.01
Stroke 14 843 (14.8) 6323 (16.7) 0.07 14 843 (14.8) 15 759 (15.8) 0.04
Atrial fibrillation/flutter 25 816 (25.7) 6925 (18.2) 0.26 25 816 (25.7) 26 164 (26.3) 0.02
Heart valve disease 9678 (9.7) 3329 (8.8) 0.04 9678 (9.7) 9991 (10.0) 0.02
Venous thromboembolism 5381 (5.4) 1965 (5.2) 0.01 5381 (5.4) 5710 (5.7) 0.02
Diabetes mellitus 29 098 (29.0) 8036 (21.2) 0.26 29 098 (29.0) 30 230 (30.3) 0.04
Chronic pulmonary disease 30 900 (30.8) 11 396 (30.0) 0.02 30 900 (30.8) 31 262 (31.4) 0.02
Renal disease 9404 (9.4) 5708 (15.0) 0.25 9404 (9.4) 10 275 (10.3) 0.04
End-stage renal disease 1417 (1.4) 1610 (4.2) 0.24 1417 (1.4) 1574 (1.6) 0.02
Liver disease 1681 (1.7) 759 (2.0) 0.03 1681 (1.7) 1696 (1.7) 0.00
Dementia 5735 (5.7) 2716 (7.2) 0.08 5735 (5.7) 5901 (5.9) 0.01
Cancer 18 573 (18.5) 7784 (20.5) 0.07 18 573 (18.5) 18 288 (18.4) 0.01
Metastatic cancer 2834 (2.8) 1312 (3.5) 0.05 2834 (2.8) 2726 (2.7) 0.01
Peptic ulcer disease 6523 (6.5) 2824 (7.4) 0.05 6523 (6.5) 6777 (6.8) 0.02
Rheumatoid arthritis or 
connective tissue disease
6562 (6.5) 2697 (7.1) 0.03 6562 (6.5) 6595 (6.6) 0.00
Comedication (prescription within 90 d)
Total number of antihypertensive drugs†
1 41 998 (41.9) 21 008 (55.3) 0.38 41 998 (41.9) 42 571 (42.7) 0.02
2 48 637 (48.5) 14 472 (38.1) 0.30 48 637 (48.5) 47 098 (47.3) 0.03
3 9352 (9.3) 2421 (6.4) 0.16 9352 (9.3) 9618 (9.7) 0.02
4 291 (0.3) 60 (0.2) 0.04 291 (0.3) 339 (0.3) 0.01
Thiazides 30 954 (30.9) 6788 (17.9) 0.43 30 954 (30.9) 32 095 (32.2) 0.04
β Blockers 35 525 (35.4) 11 735 (30.9) 0.14 35 525 (35.4) 33 406 (33.5) 0.06
Other antihypertensive 
drugs
1735 (1.7) 971 (2.6) 0.08 1735 (1.7) 1849 (1.9) 0.01
Statins 37 363 (37.3) 11 547 (30.4) 0.21 37 363 (37.3) 37 279 (37.4) 0.00
Aspirin 34 140 (34.0) 12 295 (32.4) 0.05 34 140 (34.0) 34 304 (34.4) 0.01
Loop diuretics 34 667 (34.6) 11 574 (30.5) 0.12 34 667 (34.6) 35 103 (35.2) 0.02
Immunosuppressants 1359 (1.4) 521 (1.4) 0.00 1359 (1.4) 1279 (1.3) 0.01
Glucocorticoids 15 050 (15.0) 6081 (16.0) 0.04 15 050 (15.0) 15 310 (15.4) 0.01
NSAIDs 12 334 (12.3) 4653 (12.3) 0.00 12 334 (12.3) 12 231 (12.3) 0.00
Opioids 27 563 (27.5) 11 423 (30.1) 0.08 27 563 (27.5) 28 122 (28.2) 0.02
Vitamin K antagonists 12 164 (12.1) 2863 (7.5) 0.22 12 164 (12.1) 11 842 (11.9) 0.01
Proton pump inhibitors 30 277 (30.2) 12 954 (34.1) 0.12 30 277 (30.2) 30 906 (31.0) 0.03
Antidepressants 22 736 (22.7) 9793 (25.8) 0.10 22 736 (22.7) 23 337 (23.4) 0.03
(Continued)
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regression model, including calendar time and all 
covariates listed in Table  1. We used PS-weighting 
to generate a pseudopopulation of relevant compari-
sons (eg, CCB users or ACE-I/ARB nonusers) that 
resembled the number and covariate distribution of 
ACE-I/ARB users. As we were interested in the av-
erage treatment effect in the treated, we applied 
PS-weighting using average treatment effect in the 
treated weights to make the number and covariate 
distribution in the comparison groups resemble that 
of the ACE-I/ARB users. Overlap in PS distributions 
was checked before weighting and found sufficient. 
Covariate balance was assessed by standardized 
differences, empirical cumulative distribution func-
tions for continuous variables (age and index), and 
by PS-weight percentiles. Overall, covariate balance 
was deemed acceptable, although there was some 
imbalance in small subgroups as reflected by high 
weights and standardized differences.
Follow-up started on the date of hospital con-
tact with influenza/pneumonia and continued until 
the specific outcome of interest, emigration, or up to 
30 days, whichever occurred first. The 30-day risk of 
death and ICU admission was computed and plotted, 
both crude and PS-weighted. Risk differences (RDs) 
were computed for all outcomes by subtracting PS-
weighted risks. Risk ratios (RRs) were estimated as the 
ratio of PS-weighted risk estimates. All estimates were 
presented with 95% CIs obtained through bootstrap-
ping with 200 bootstrap samples.
Additional analyses were performed to examine the 
robustness of our findings.
First, we changed the exposure definition to make 
a head-to-head comparison between ACE-I/ARB 
and β blockers and thiazides, respectively. Second, 
we compared monotherapy with ACE-I/ARB with 
CCB monotherapy. Third, analyses were repeated 
using only the primary (first-listed) diagnoses of in-
fluenza or pneumonia. Fourth, analyses were strat-
ified by age at the index date (18–65  years and 
>65 years). Fifth, analyses were repeated according 
to potential underlying indications for treatment in-
cluding patients with renal disease, with congestive 
heart failure, with ischemic heart disease (myocar-
dial infarction or stable angina pectoris), with diabe-
tes mellitus, and without any of these comorbidities, 
and in patients without any of these comorbidities 
who had a hospital diagnosis of hypertension. Sixth, 
we repeated the analyses restricted to patients cur-
rently using more than 1 antihypertensive medica-
tion (polytherapy). Finally, we stratified by hospital 
versus community-acquired pneumonia defined as 
no hospital contract within 3 to 30 days before study 
inclusion.
All statistical analyses were performed using SAS 
version 9.4 (SAS Institute, Cary, NC).
Overall Cohort PS-Weighted Cohort
Current ACE-I/ 
ARB Use, 
N (%)
Current  
CCB Use, 
N (%) SD
Current ACE-I/ 
ARB Use, 
N (%)
Current  
CCB Use*, 
N (%) SD
Hypnotics/sedatives 15 720 (15.7) 6517 (17.2) 0.06 15 720 (15.7) 15 976 (16.0) 0.01
Antipsychotics 5508 (5.5) 2551 (6.7) 0.07 5508 (5.5) 5433 (5.5) 0.00
Antibiotics (prescription 
within 10 d)
26 448 (26.4) 9973 (26.3) 0.00 26 448 (26.4) 26 235 (26.3) 0.00
Antivirals (prescription within 
10 d)
226 (0.2) 84 (0.2) 0.00 226 (0.2) 194 (0.2) 0.01
Lifestyle and social factors
Markers of smoking 52 541 (52.4) 19 033 (50.1) 0.06 52 541 (52.4) 52 447 (52.6) 0.01
Obesity 10 262 (10.2) 2719 (7.2) 0.15 10 262 (10.2) 10 785 (10.8) 0.03
Alcoholism 6107 (6.1) 2381 (6.3) 0.01 6107 (6.1) 5925 (5.9) 0.01
Marital status
Widow 31 850 (31.8) 13 837 (36.5) 0.14 31 850 (31.8) 33 295 (33.4) 0.05
Divorced 14 243 (14.2) 5368 (14.1) 0.00 14 243 (14.2) 14 118 (14.2) 0.00
Married 46 171 (46.0) 15 841 (41.7) 0.12 46 171 (46.0) 44 607 (44.8) 0.04
Unmarried 8014 (8.0) 2915 (7.7) 0.02 8014 (8.0) 7604 (7.6) 0.02
Urban residence 34 592 (34.5) 12 629 (33.3) 0.04 34 592 (34.5) 34 848 (35.0) 0.01
ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; PS, propensity score; 
and SD, standardized difference.
*Pseudopopulation of current CCB users weighted to the PS distribution of current ACE-I/ARB users.
†Number of antihypertensive drugs including the exposure of interest (ACE-Is/ARBs or CCBs, thiazides, β blockers, and other (range from 1 to 4 because 
patients using both ACE-I/ARBs and CCBs are not included).
Table 1. Continued
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RESULTS
The final study cohort included 568 019 adult Danish 
residents hospitalized for influenza or pneumonia 
(Figure  1): 100  278 (17.7%) were current ACE-I/ARB 
users, 37  961 (6.7%) were current CCB users, and 
33 155 (5.8%) were current users of both. There were 
9413 admissions for influenza and 518 296 for pneu-
monia with bacterial or unspecified pathogen. Of the 
overall cohort of influenza/pneumonia, 454 303 (79.8%) 
were community-acquired and 114 716 (20.2%) were 
hospital-acquired.
A total of 42 827 hospitalizations included admission 
to the ICU; for most of these patients, ICU transferal 
happened early (median of 1 day, 25th–75th percen-
tiles: 0–5 days) after first hospital admission. A total of 
76 762 died within 30 days. Patient characteristics of 
the final study cohort are provided in Table S2 overall, 
and by death within 30 days and ICU admission.
Descriptive Characteristics of ACE-I/ARB 
and CCB Users
Median age was almost similar in ACE-I/ARB and CCB 
users (76.9 versus 78.8  years). There were slightly 
more men among ACE-I/ARB users than among CCB 
users (53.7% versus 48.7%). ACE-I/ARB users had a 
higher prevalence of most cardiovascular diseases, 
including heart failure, myocardial infarction, and dia-
betes mellitus. In contrast, hypertension and renal 
disease were less frequent in ACE-I/ARB users than 
in CCB users (Table 1). Comedication with most car-
diovascular medications, including other antihyperten-
sive drugs, was more frequent in ACE-I/ARB users. In 
both groups, 26% of patients had received antibiotics 
within 10 days prior to hospital admission. Markers of 
smoking and alcohol-related disorders were equally 
prevalent in both groups; obesity was more common 
in ACE-I/ARB users.
After PS-weighting of CCB users, treatment groups 
were well-balanced on all measured covariates, with 
absolute standardized differences for all covariates 
decreasing from 0.00 to 0.55 before PS-balancing to 
<0.10 (Table 1).
Outcomes in ACE-I/ARB Versus CCB 
Users
Table 2 shows the number of outcome events, risks, 
RDs, and RRs after PS-weighting of CCB users. The 
Table 2. Outcomes in Current Users of ACE-Is or ARBs Compared With CCBs, Adjusted by PS-Weighting and Stratified by 
Influenza and Pneumonia With Bacterial or Unspecified Pathogen
Population Event
ACE-Is/ARBs CCBs
Risk Difference* % 
(95% CI) vs CCBs
Risk Ratio* 
(95% CI) vs  
CCBsEvents/at Risk Risk % Events/at Risk* Risk* %
Any influenza 
or pneumonia
30-d mortality 13 940/100 278 13.9% 14 412/99 625 14.5% −0.6 (−1.0 to −0.1) 0.96 (0.93–0.99)
ICU admission 7993/100 278 8.0% 9558/99 625 9.6% −1.6 (−2.0 to −1.2) 0.83 (0.80–0.87)
ICU+MV 4218/100 278 4.2% 5196/99 625 5.2% −1.0 (−1.3 to −0.7) 0.81 (0.76–0.86)
ICU+NIV 3039/100 278 3.0% 4132/99 625 4.1% −1.1 (−1.4 to −0.8) 0.73 (0.68–0.79)
ICU+inotropes/
vasopressors
3825/100 278 3.8% 3877/99 625 3.9% −0.1 (−0.3 to 0.2) 0.98 (0.92–1.05)
D-AKI 965/98 861 1.0% 1296/98 534 1.3% −0.3 (−0.5 to −0.1) 0.74 (0.64–0.86)
Influenza 30-d mortality 82/1565 5.2% 60/1516 3.9% 1.3 (−1.2 to 3.8) 1.33 (0.69–2.55)
ICU admission 129/1565 8.2% 146/1516 9.6% −1.4 (−5.7 to 3.0) 0.86 (0.53–1.39)
ICU+MV 70/1565 4.5% 70/1516 4.6% −0.2 (−2.9 to 2.6) 0.96 (0.52–1.80)
ICU+NIV 63/1565 4.0% 55/1516 3.6% 0.4 (−1.6 to 2.3) 1.11 (0.65–1.88)
ICU+inotropes/
vasopressors
61/1565 3.9% 55/1516 3.6% 0.3 (−2.4 to 2.9) 1.07 (0.51–2.25)
D-AKI 15/1514 1.0% <5/1504 0.3% 0.7 (0.1–1.3) 3.40 (0.96–12.02)
Pneumonia 
with bacterial 
or unspecified 
pathogen†
30-d mortality 13 140/93 193 14.1% 13 572/92 542 14.7% −0.6 (−1.1 to −0.0) 0.96 (0.93–1.00)
ICU admission 7456/93 193 8.0% 8912/92 542 9.6% −1.6 (−2.1 to −1.2) 0.83 (0.79–0.87)
ICU+MV 3918/93 193 4.2% 4788/92 542 5.2% −1.0 (−1.3 to −0.7) 0.81 (0.76–0.87)
ICU+NIV 2839/93 193 3.0% 3890/92 542 4.2% −1.2 (−1.5 to −0.9) 0.72 (0.67–0.78)
ICU+inotropes/
vasopressors
3567/93 193 3.8% 3587/92 542 3.9% −0.0 (−0.3 to 0.2) 0.99 (0.92–1.07)
D-AKI 886/91 899 1.0% 1185/91 538 1.3% −0.3 (−0.5 to −0.2) 0.74 (0.65–0.86)
ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; D-AKI, dialysis-treated 
acute kidney injury; ICU, intensive care unit; MV, mechanical ventilation; NIV, noninvasive ventilation; and PS, propensity score.
*Pseudopopulation of current CCB users weighted to the PS distribution of current ACE-I/ARB users.
†Not including viral pneumonia and influenza without proven influenza virus.
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crude estimates are provided in Table 3. The cumula-
tive incidence (risk) plots before (crude-) and after PS-
weighting (adjusted) are given in Figure 2A and 2B.
Among all patients with influenza or pneumonia, 
30-day mortality was 13.9% in ACE-I/ARB users 
and 14.5% in CCB users, with a corresponding RD 
of −0.6% (95% CI, −1.0 to −0.1) and a RR of 0.96 
(95% CI, 0.93–0.99). The risk of ICU admission was 
8.0% in ACE-I/ARB users and 9.6% in CCB users, 
corresponding to an RD of −1.6% (95% CI, −2.0 to 
−1.2) and an RR of 0.83 (95% CI, 0.80–0.87) for 
ACE-I/ARB users compared with CCB users. The 
estimates were similar for ICU admissions with need 
for mechanical ventilation, noninvasive ventilation, 
and dialysis-treated acute kidney injury. There was 
no difference in risk of ICU admission including 
treatment with inotropes/vasopressors (RD, −0.1%; 
95% CI, −0.3 to 0.2).
In the subgroup of patients diagnosed with influ-
enza, 30-day mortality was 5.2% in ACE-I/ARB users 
and 3.9% in CCB users (RD, 1.3%; 95% CI, −1.2 to 3.8; 
RR, 1.33, 95% CI, 0.69–2.55). The risk of ICU admis-
sion was 8.2% in ACE-I/ARB users and 9.6% in CCB 
users (RD, −1.4%; 95% CI, −5.7 to 3.0; RR, 0.86; 95%, 
CI, 0.53–1.39). Risk of ICU admission with need for 
mechanical ventilation was similar in ACE-I/ARB and 
CCB users (4.5% versus 4.6%).
Characteristics and Outcomes in Current 
Users of ACE-Is/ARBs Compared With 
Nonusers
The patient characteristics of all current ACE-I/ARB 
users and nonusers were reasonably balanced after 
PS-weighting, with only a few standardized differences 
above 0.10 (Table 4).
ACE-I/ARB users had lower 30-day mortality than 
nonusers (13.5% versus 15.9%; Table  5). The corre-
sponding RD was −2.4% (95% CI, −2.8 to −2.0) and 
the RR was 0.85 (95% CI, 0.83–0.87). The risk of ICU 
admission was similar among users and nonusers 
(8.4% versus 8.1%; RD, 0.4%; 95% CI, 0.0–0.7; RR, 
1.04; 95% CI, 1.00–1.09). When compared with non-
users, former ACE-I/ARB users did not have increased 
mortality, but they did have a decreased risk of ICU 
admission (Figure 3). Crude estimates are provided in 
Table 6.
Table 3. Crude Outcomes in Current Users of ACE-Is or ARBs Compared With CCBs, Overall and Stratified by Influenza 
and Pneumonia With Bacterial or Unspecified Pathogen
Population Event
ACE-Is/ARBs CCBs
Risk Difference* % 
(95% CI) vs CCBs
Risk Ratio* 
(95% CI) vs CCBsEvents/At Risk Risk % Events/At Risk* Risk* %
Any influenza 
or pneumonia
30-d mortality 13 940/100 278 13.9 6016/37 961 15.8 −1.9 (−2.4 to −1.5) 0.88 (0.85–0.90)
ICU admission 7993/100 278 8.0 3321/37 961 8.7 −0.8 (−1.1 to −0.5) 0.91 (0.88–0.94)
ICU+MV 4218/100 278 4.2 1753/37 961 4.6 −0.4 (−0.6 to −0.2) 0.91 (0.87–0.95)
ICU+NIV 3039/100 278 3.0 1468/37 961 3.9 −0.8 (−1.0 to −0.6) 0.78 (0.74–0.83)
ICU+inotropes/
vasopressors
3825/100 278 3.8 1322/37 961 3.5 0.3 (0.1–0.5) 1.10 (1.04–1.16)
D-AKI 965/98 861 1.0 438/36 351 1.2 −0.2 (−0.4 to −0.1) 0.81 (0.72–0.92)
Influenza 30-d mortality 82/1565 5.2 25/526 4.8 0.5 (−1.6 to 2.5) 1.10 (0.71–1.71)
ICU admission 129/1565 8.2 44/526 8.4 −0.1 (−2.8 to 2.6) 0.99 (0.70–1.38)
ICU+MV 70/1565 4.5 24/526 4.6 −0.1 (−2.1 to 1.9) 0.98 (0.62–1.56)
ICU+NIV 63/1565 4.0 28/526 5.3 −1.3 (−3.5 to 0.9) 0.76 (0.47–1.21)
ICU+inotropes/
vasopressors
61/1565 3.9 20/526 3.8 0.1 (−1.8 to 2.0) 1.03 (0.62–1.69)
D-AKI 15/1514 1.0 <5/449 0.7 0.3 (−0.5 to 1.2) 1.48 (0.45–4.84)
Pneumonia 
with bacterial 
or unspecified 
pathogen
30-d mortality 13 140/93 193 14.1 5683/35 426 16.0 −1.9 (−2.4 to −1.5) 0.88 (0.85–0.91)
ICU admission 7456/93 193 8.0 3123/35 426 8.8 −0.8 (−1.2 to −0.5) 0.91 (0.87–0.95)
ICU+MV 3918/93 193 4.2 1640/35 426 4.6 −0.4 (−0.7 to −0.2) 0.91 (0.86–0.96)
ICU+NIV 2839/93 193 3.0 1389/35 426 3.9 −0.9 (−1.1 to −0.7) 0.78 (0.73–0.83)
ICU+inotropes/
vasopressors
3567/93 193 3.8 1240/35 426 3.5 0.3 (0.1–0.6) 1.09 (1.02–1.17)
D-AKI 886/91 899 1.0 407/33 983 1.2 −0.2 (−0.3 to −0.1) 0.80 (0.73–0.89)
ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; D-AKI, dialysis-treated 
acute kidney injury; ICU, intensive care unit; MV, mechanical ventilation; NIV, noninvasive ventilation; and PS, propensity score.
*Pseudopopulation of current CCB users weighted to the PS distribution of current ACE-I/ARB users.
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Figure 2. Crude (A) and propensity score-weighted (B) 30-day cumulative incidence (risk) and relative risk (RR) of death 
and intensive care unit (ICU) admission in patients with influenza or pneumonia, with only influenza, and with pneumonia 
with bacterial or unspecified pathogen.
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
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Additional Analyses
The head-to-head comparisons of ACE-Is/ARBs with 
β blockers and thiazides, respectively, showed that 
30-day mortality was also lowered in ACE-I/ARB users 
when compared with these other drugs, whereas there 
was no difference in risk of ICU admission (Figure 3).
ACE-I/ARB monotherapy users did not have in-
creased mortality, but decreased absolute and rela-
tive risk of ICU admission when compared with CCB 
monotherapy (Figure 3).
Restriction to patients with a first-listed diagno-
sis of influenza or pneumonia reduced the number 
of current ACE-I/ARB users to 69 373 and current 
CCB users to 26 006. PS-weighted 30-day mortal-
ity was 11.3% in ACE-/ARB users and 11.8% in CCB 
users. The corresponding RR was 0.96 (95% CI, 
0.92–1.01). Relative risk of ICU admission was also 
similar to that obtained in the main analyses (RR, 
0.80; 95% CI, 0.74–0.87; Figure  3). The subgroup 
analyses by age and coexisting conditions were 
overall robust and compatible with our main find-
ings. In patients without any other conditions than 
hypertension, current ACE-I/ARB users had lower 
absolute and relative risks of both death and ICU 
admission (Figure 3). Our findings were robust also 
when restricting to patients on more than one an-
tihypertensive medication (polytherapy), and when 
stratifying by hospital- and community-acquired 
pneumonia (Figure 3).
DISCUSSION
In this cohort study of patients with influenza or pneu-
monia, we found that ACE-I/ARB users had no in-
creased risk of ICU admissions and a slightly reduced 
mortality, after controlling for coexisting conditions and 
comedications. The findings were robust across vari-
ous different exposure definitions, subgroups, and also 
when compared with other antihypertensive drugs. We 
observed reduced risks of both ICU admission and 
mortality in some subgroups of ACE-I/ARB users, in-
cluding patients with hypertension and no other car-
diometabolic conditions.
Our study extends findings from previous smaller 
studies of pneumonia mortality. Our observed 
Table 5. Outcomes in Current Users of ACE-Is or ARBs Compared With Nonusers, Adjusted by PS-Weighting and Stratified 
by Influenza and Pneumonia With Bacterial or Unspecified Pathogen
Population Event
Current ACE-I/ARB Use ACE-I/ARB Nonuse Risk Difference % 
(95% CI) vs  
Nonuse*
Risk Ratio 
(95% CI)  
vs Nonuse*Events/At Risk Risk % Events/At Risk* Risk* %
Any influenza 
or pneumonia
30-d mortality 18 017/133 433 13.5% 24 273/153 032 15.9% −2.4 (−2.8 to −2.0) 0.85 (0.83–0.87)
ICU admission 11 225/133 433 8.4% 12 332/153 032 8.1% 0.4 (0.0–0.7) 1.04 (1.00–1.09)
ICU+MV 5965/133 433 4.5% 6600/153 032 4.3% 0.2 (−0.1 to 0.4) 1.04 (0.98–1.10)
ICU+NIV 4424/133 433 3.3% 5219/153 032 3.4% −0.1 (−0.3 to 0.1) 0.97 (0.91–1.04)
ICU+inotropes/
vasopressors
5352/133 433 4.0% 5294/153 032 3.5% 0.6 (0.3–0.8) 1.16 (1.08–1.24)
D-AKI 1455/130 875 1.1% 1617/150 516 1.1% 0.0 (−0.1 to 0.2) 1.03 (0.89–1.20)
Influenza 30-d mortality 110/2110 5.2% 182/2447 7.4% −2.2 (−5.0 to 0.5) 0.70 (0.47–1.05)
ICU admission 191/2110 9.1% 212/2447 8.7% 0.4 (−1.9 to 2.7) 1.04 (0.80–1.37)
ICU+MV 118/2110 5.6% 109/2447 4.4% 1.1 (−0.5 to 2.8) 1.26 (0.89–1.78)
ICU+NIV 94/2110 4.5% 99/2447 4.1% 0.4 (−1.3 to 2.1) 1.10 (0.74–1.63)
ICU+inotropes/
vasopressors
103/2110 4.9% 93/2447 3.8% 1.1 (−0.3 to 2.5) 1.29 (0.91–1.82)
D-AKI 22/2014 1.1% 30/2363 1.3% −0.2 (−1.3 to 0.9) 0.86 (0.36–2.07)
Pneumonia 
with bacterial 
or unspecified 
pathogen†
30-d mortality 16 979/124 054 13.7% 22 644/141 687 16.0% −2.3 (−2.7 to −1.9) 0.86 (0.83–0.88)
ICU admission 10 482/124 054 8.4% 11 361/141 687 8.0% 0.4 (0.1–0.8) 1.05 (1.01–1.10)
ICU+MV 5529/124 054 4.5% 5990/141 687 4.2% 0.2 (−0.0 to 0.5) 1.05 (0.99–1.12)
ICU+NIV 4151/124 054 3.3% 4853/141 687 3.4% −0.1 (−0.3 to 0.2) 0.98 (0.91–1.05)
ICU+inotropes/
vasopressors
4973/124 054 4.0% 4817 3.4% 0.6 (0.4–0.9) 1.18 (1.10–1.26)
D-AKI 1343/121 749 1.1% 1422 1.0% 0.1 (−0.0 to 0.2) 1.08 (0.95–1.23)
ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; D-AKI, dialysis-treated acute kidney injury; ICU, intensive 
care unit; MV, mechanical ventilation; NIV, noninvasive ventilation; and PS, propensity score.
*Pseudopopulation of nonusers weighted to the PS distribution of current ACE-I/ARB users.
†Not including viral pneumonia and influenza without proven influenza virus.
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associations were weaker than reported in previous 
studies.16–18 A previous meta-analysis of 3 trials and 
4 observational studies with data on pneumonia-re-
lated mortality reported decreased odds for mortality 
in ACE-I users compared with nonusers (OR, 0.73; 
95% CI, 0.58–0.92), but most of the studies exam-
ined were not designed to address this topic, as 
ACE-I was not their main exposure, and several stud-
ies mixed pneumonia risk and outcomes.16 In a later 
US study including 8652 pneumonia patients aged 
≥65 years, ACE-I use prior to hospitalization also was 
associated with reduced 30-day mortality (adjusted 
OR, 0.80; 95% CI, 0.68–0.89).17 Another US study 
that examined the association between cardiovascu-
lar medication in 21 985 elderly patients hospitalized 
with pneumonia reported an adjusted OR for 90-
day mortality of 0.82 (95% CI, 0.74–0.91) for ACE-I 
users and 0.58 (95% CI, 0.44–0.77) for ARB users.18 
In contrast, a US study of patients hospitalized with 
mixed viral disease found that preadmission ACE-I 
use was associated with increased mortality (OR, 
3.02; 95% CI, 1.30–7.01) and increased intubation 
rates among the 539 patients admitted with pneumo-
nia.19 In that study, in-hospital ACE-I use was associ-
ated with substantially lowered mortality, which may 
be biased as the drug may only be continued during 
hospitalization in patients without severe illness.19 
Such bias may also explain the lower mortality (OR, 
0.37; 95% CI, 0.15–0.89) among in-hospital users 
of ACE-Is/ARBs in a recent Chinese study of 1128 
patients with COVID-19.20 Another recent Chinese 
study of 1178 patients found no association between 
in-hospital use of ACE-Is/ARBs and the severity and 
mortality of patients with COVID-19.21
The mechanism behind our findings is not clear. 
ACE2 expression, which is probably increased in 
Figure 3. Thirty-day mortality and risk of intensive care unit (ICU) admission by different exposure definitions and subgroups.
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and CCB, calcium channel blocker.
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ACE-I/ARB-treated patients, may protect against 
the development of severe acute lung injury,13,28,29 In 
contrast, it has been suggested that the ACE-I/ARB-
induced increase in cell-surface ACE2 expression 
may increase the risk and severity of severe acute 
respiratory syndrome-coronavirus and severe acute 
respiratory syndrome-coronavirus 2 specifically.13 The 
contradictions are addressed in planned trials on the 
impact of losartan on organ dysfunction and mortality 
in patients hospitalized with COVID-19 (Clini calTr ials.
gov Identifier: NCT04312009 and NCT04328012).
Although the current study was conducted in 
Denmark’s population-based hospital setting using val-
idated registries with complete follow-up on all Danish 
residents, it also had limitations. Observational stud-
ies of drug effects have inherent methodological chal-
lenges, and our results should therefore be interpreted 
with caution. Ultimately, a randomized controlled trial 
would be needed to draw firm conclusions regarding 
ACE-I/ARB effects on ICU admission and mortality in 
patients with influenza or pneumonia.
Study inclusion relied on coding of influenza and 
pneumonia. Although some patients may not receive a 
diagnosis, we believe the restriction to physician-coded 
influenza and pneumonia discharge diagnoses meant 
that only patients with clinically relevant infections were 
included. The positive predictive value of pneumonia 
diagnoses in the patient registry is 90%.30 Of patients 
diagnosed with influenza, 66% had a positive influenza 
test (A. Pottegård, MSc, PhD, DMSc, unpublished 
data, 2020). Any selection bias should be minimal be-
cause follow-up was virtually complete, and different 
associations between included and nonincluded pa-
tients are not expected.
Medication use was assessed using prescriptions 
prior to hospitalization in a time window correspond-
ing to the typical interval between medication dis-
pensings.27 Still, misclassification may occur if some 
patients had a sporadic use of drugs filled more than 
90 days before hospitalization. Given the chronic use 
of the drugs included in the study, any misclassification 
should be minor and not associated with the outcome 
of interest. Any information bias is therefore expected 
to be towards null. We lacked in-hospital medication 
data to examine the impact of prescribed and discon-
tinued drugs during follow-up.
Death is accurately recorded in the population regis-
try with daily updates.24 ICU admissions and treatments 
are also accurately recorded, as the patient registry has 
been used for financial reimbursement of hospitals, and 
for mandatory reporting to national quality of care data-
bases during the study period.26,31 Use of ICU admission 
Table 6. Crude Outcomes in Current Versus Nonusers of ACE-Is or ARBs, Overall and Stratified by Influenza and 
Pneumonia With Bacterial or Unspecified Pathogen
Population Event
ACE-I/ARB Use Nonuse Risk Difference % 
(95% CI)  
vs Nonuse
Risk Ratio (95% 
CI) vs NonuseEvents/At Risk Risk % Events/At risk† Risk† %
Any influenza 
or pneumonia
30-d mortality 18 017/133 433 13.5 51 229/388 790 13.2 0.3 (0.1–0.5) 1.02 (1.01–1.04)
ICU admission 11 225/133 433 8.4 27 668/388 790 7.1 1.3 (1.1–1.5) 1.18 (1.16–1.21)
ICU+MV 5965/133 433 4.5 15 300/388 790 3.9 0.5 (0.4–0.7) 1.14 (1.11–1.17)
ICU+NIV 4424/133 433 3.3 10 224/388 790 2.6 0.7 (0.6–0.8) 1.26 (1.22–1.31)
ICU+inotropes/
vasopressors
5352/133 433 4.0 11 547/388 790 3.0 1.0 (0.9–1.2) 1.35 (1.31–1.40)
D-AKI 1455/130 875 1.1 2561/383 925 0.7 0.4 (0.4–0.5) 1.67 (1.55–1.79)
Influenza 30-d mortality 110/2110 5.2 296/6581 4.5 0.7 (−0.5 to 1.9) 1.16 (0.92–1.45)
ICU admission 191/2110 9.1 497/6581 7.6 1.5 (0.0–3.0) 1.20 (1.01–1.42)
ICU+MV 118/2110 5.6 336/6581 5.1 0.5 (−0.7 to 1.7) 1.10 (0.88–1.36)
ICU+NIV 94/2110 4.5 228/6581 3.5 1.0 (−0.0 to 2.0) 1.29 (1.01–1.64)
ICU+inotropes/
vasopressors
103/2110 4.9 282/6581 4.3 0.6 (−0.5 to 1.6) 1.14 (0.91–1.43)
D-AKI 22/2014 1.1 78/6386 1.2 −0.1 (−0.6 to 0.4) 0.89 (0.58–1.38)
Pneumonia 
with bacterial 
or unspecified 
pathogen
30-d mortality 16 979/124 054 13.7 48 206/351 722 13.7 −0.0 (−0.2 to 0.2) 1.00 (0.98–1.02)
ICU admission 10 482/124 054 8.4 25 667/351 722 7.3 1.2 (1.0–1.3) 1.16 (1.13–1.18)
ICU+MV 5529/124 054 4.5 14 056/351 722 4.0 0.5 (0.3–0.6) 1.12 (1.08–1.15)
ICU+NIV 4151/124 054 3.3 9518/351 722 2.7 0.6 (0.5–0.8) 1.24 (1.19–1.28)
ICU+inotropes/
vasopressors
4973/124 054 4.0 10 632/351 722 3.0 1.0 (0.9–1.1) 1.33 (1.28–1.37)
D-AKI 1343/121 749 1.1 2320/347 374 0.7 0.4 (0.4–0.5) 1.65 (1.54–1.77)
ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; D-AKI, dialysis-treated acute kidney injury; ICU, intensive 
care unit; MV, mechanical ventilation; and NIV, noninvasive ventilation.Dow
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as an outcome in observational prognostic studies is 
challenging. In clinical practice, ICU admission is offered 
to patients who are expected to have a clear prognostic 
benefit from invasive monitoring and treatment.32 In ad-
dition, the patients’ quality of life and functional level at 
home and hospital capacity may influence the decision 
to admit a patient to the ICU. This may explain why ICU 
and mortality outcomes tended to go in opposite direc-
tions for some of the associations examined in our study.
Potential confounding by medical indication for 
drug treatment was handled by using an active com-
parator in the main analysis, by using PS-weighting in-
cluding a large number of potential confounders, and 
by restriction to subgroups according to indication for 
treatment. We observed and accounted for a higher 
use of antihypertensive and other cardiovascular 
medications in ACE-I/ARB users in our analysis. The 
higher use may be explained by the higher prevalence 
of heart diseases observed with ACE-I/ARB use. For 
example, the higher prevalence of vitamin K antago-
nist use may be explained by the higher prevalence 
of atrial fibrillation in ACE-I/ARB users compared with 
CCB users. On the other hand, the prevalence of eg 
kidney disease or dementia was lower in ACE-I/ARB 
users than in CCB users, indicating cautious use of 
ACE-I/ARB among patients with kidney disease and 
more frailty among CCB users. This may have contrib-
uted to the lower unadjusted relative risk (RR=0.88) of 
death in ACE-I/ARB users compared with CCB-users, 
which attenuated after PS-weighting (RR=0.96).
Although cardiovascular and other diagnoses used 
in the study have documented high positive predictive 
values,20,33 we cannot entirely rule out that our findings 
of a potential beneficial effect of ACE-I/ARB use were in-
fluenced by unmeasured confounding by indication and 
contraindication. Healthy user bias is, however, an un-
likely explanation of the findings as the captured lifestyle 
factors did not indicate any healthier lifestyle in ACE-I/
ARB users compared with CCB users. Finally, although 
our study included more than 500 000 patients, preci-
sion of risk estimates was limited in some subgroups.
In conclusion, ACE-I/ARB users hospitalized with 
influenza or pneumonia had no increased risk of ICU 
admission and a lower mortality after controlling for 
confounding. Thus, our data support the current rec-
ommendations1,21 to avoid discontinuation of ACE-Is/
ARBs during the COVID-19 pandemic, unless future 
evidence contradicts our findings.
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SUPPLEMENTAL MATERIAL
D
ow
nloaded from
 http://ahajournals.org by on D
ecem
ber 11, 2020
Table S1. Codes.
Variable Source/format Look-
back 
Inclusion codes Exclusion 
codes 
Study population (ICD-10 codes) 
Any influenza or pneumonia DNPR/ICD-10 J09-J18, A481, B012, 
A709 
  Influenza DNPR/ICD-10 J09, J10 
  Pneumonia with bacterial or 
unspecified pathogen 
DNPR/ICD-10 J13, J14, J157, J159, 
J180, J181, J182, J189, 
A481 
Main exposures (ATC codes) 
ACE-Is NPD/ATC 90d C09A, C09B 
ARBs NPD/ATC 90d C09C, C09D 
Calcium channel blockers (CCB) NPD/ATC 90d C07FB, C08CA, C09BB, 
C09DB, C09DX01 
Outcomes  
ICU admission DNPR/Procedure NABE, NABB 
  Mechanical ventilation DNPR/Procedure BGDA0 
  Non-invasive ventilation DNPR/Procedure BGDA1 
  Treatment with 
inotropes/vasopressors 
DNPR/Procedure BFHC92A,  BFHC92B,  
BFHC92C,  BFHC92D, 
BFHC92E, BFHC93A, 
BFHC93B, BFHC93C, 
BFHC95 
Dialysis-treated acute kidney injury 
(“acute dialysis”) 
DNPR/Procedure BJFD0 
Death CPR/status 
Covariates 
Age CPR 
Sex CPR 
Coexisting conditions 
Hospital-diagnosed hypertension DNPR/ICD-10 10y I10, I15 
Diagnosed stable angina pectoris DNPR/ICD-10 10y I20, I251, I259 I21, I22, 
I23, I200 
Myocardial infarction DNPR/ICD-10 10y I21, I22, I23 
Heart failure DNPR/ICD-10 10y I50 
Stroke DNPR/ICD-10 10y I60, I61, I63, I64 
Atrial fibrillation/flutter DNPR/ICD-10 10y I48 
Heart valve disease DNPR/ICD-10 10y I05, I06, I07, I08, I09.8, 
I34-I37, I39, I51.1A, Q22, 
Q23 
Venous thromboembolism DNPR/ICD-10 10y I26, I801, I802, I803 
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Variable Source/format Look-
back 
Inclusion codes Exclusion 
codes 
Diabetes DNPR/ICD-10 10y E10, E11, E12, E13, E14, 
O24, G63.2, H360, N083 
O24.4 
NPD/ATC 10y A10A, A10B 
Chronic pulmonary disease DNPR/ICD-10 10y J40, J41-J44, J45−J47, 
J60−J67, J68.4, J70.1, 
J70.3, J84.1, J92.0, J96.1, 
J98.2, J98.3 
Renal disease DNPR/ICD-10 10y I12, I13, N00−N05, N07, 
N11, N14, N18−N19, Q61, 
N08, E102, E112, E142 
End-stage renal disease (kidney 
transplant or dialysis) 
DNPR/Procedure 10y BJFD2 
DNPR/Surgery 10y KKAS 
DNPR/ICD-10 10y T861, Z940 
Liver disease DNPR/ICD-10 10y B18, B150, B160, B162, 
B190, I85, K70, K71, K72, 
K73, K74, K760, K76.6 
Dementia DNPR/ICD-10 10y DF00, DF01, DF02, DF03, 
DG30, DG310B, DG311, 
DG318, DG319 
NPD/ATC 10y N06D 
Cancer DNPR/ICD-10 10y C00−C96, D459, D46, 
D471, D473, D474, D475 
C44 
Metastatic cancer DNPR/ICD-10 10y C76−C80, CxxxM 
Peptic ulcer disease DNPR/ICD-10 10y K221, K25-K28 
Rheumatoid arthritis or connective 
tissue disease 
DNPR/ICD-10 10y M05-M06, M30–M36, M45 
Co-medication 
Number of antihypertensive drugs NPD/ATC 90d 0-5 (see below: ACE-
I/ARB, CCB,
Thiazides/diuretics, BB,
other antihypertensive
drugs)
Thiazides/diuretics NPD/ATC 90d C03AA01, C03AA03,
C03AB01, C03AB03,
C03AX01, C03EA, C07B,
C09BA, C09DA,
C09DX01, C09DX03,
C09XA52, C09XA54
C07BA06 
C09BA04 
Beta-blockers (BB) NPD/ATC 90d C07
Other antihypertensive drugs NPD/ATC 90d C02AC, C02CA, 
C03BA11, C09XA 
C02AB01 
C09XA54 
Statins NPD/ATC 90d C10AA, C10B 
Aspirin NPD/ATC 90d B01AC06, N02BA01, 
N02BA51 
Loop diuretics NPD/ATC 90d C03C 
Antibiotics NPD/ATC 10d J01 
Antivirals NPD/ATC 10d J05 
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Variable Source/format Look-
back 
Inclusion codes Exclusion 
codes 
Immunosuppressants NPD/ATC 90d L04 
Glucocorticoids NPD/ATC 90d H02AB 
NSAID use NPD/ATC 90d M01A 
Opioid use NPD/ATC 90d N02A, N07BC02 
Vitamin K antagonists NPD/ATC 90d B01AA 
Proton pump inhibitors NPD/ATC 90d A02BC 
Antidepressants NPD/ATC 90d N06A 
Hypnotics/sedatives NPD/ATC 90d N05C 
Antipsychotics NPD/ATC 90d N05A 
Lifestyle and social factors 
Markers of smoking (diagnoses or 
medications for tobacco smoking or 
chronic obstructive pulmonary 
disease) 
DNPR/ICD-10 10y J41-J44, DF17, DZ716, 
DZ720 
NPD/ATC 10y R03, N07BA 
Obesity diagnoses or medications DNPR/ICD-10 10y E66 
NPD/ATC 10y A08 
Alcoholism-related diagnoses or 
medication for alcohol deterrent 
DNPR/ICD-10 10y DF10, DE244, DG312, 
DG621, DG721, DI426, 
DK292, DK70, DK852, 
DK860, DQ860, DZ502, 
DZ714, DZ721 
F100 
NPD/ATC 10y V03AA, N07BB 
Marital status (widow, divorced, 
married, umarried) 
CPR 
Rural/urban place of residence CPR 
ATC Anatomical Therapeutic Chemical Classification System; CPR Danish Civil Reigistration System; DNPR Danish National 
Patient Registry; ICD-10 International Classification of Diseases 10th edition; NPD National Prescription Database. 
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Table S2. Characteristics all influenza/pneumonia patients, overall and by main outcomes. 
Death within 30 
days ICU admission 
Overall study 
population 
Number of patients 76 762 (100.0) 42 827 (100.0) 568 019 (100.0) 
Age, median (Q1–Q3) 81.7 (73.0–88.0) 70.4 (60.4–78.7) 73.4 (60.5–82.9) 
Male 41 696 (54.3) 24 945 (58.2) 290 847 (51.2) 
Coexisting conditions (within prior 10 years) 
Hospital-diagnosed hypertension 26 779 (34.9) 13 096 (30.6) 168 929 (29.7) 
Previous myocardial infarction 6 650 (8.7) 3 225 (7.5) 39 765 (7.0) 
Diagnosis of stable angina pectoris 10 512 (13.7) 4 932 (11.5) 68 458 (12.1) 
Heart failure 13 714 (17.9) 5 745 (13.4) 71 110 (12.5) 
Stroke 13 312 (17.3) 4 745 (11.1) 65 390 (11.5) 
Atrial fibrillation/flutter 18 205 (23.7) 6 782 (15.8) 95 028 (16.7) 
Heart valve disease 6 330 (8.2) 2 775 (6.5) 34 773 (6.1) 
Venous thromboembolism 4 475 (5.8) 2 028 (4.7) 28 527 (5.0) 
Diabetes 14 424 (18.8) 8 797 (20.5) 96 530 (17.0) 
Chronic pulmonary disease 20 574 (26.8) 12 982 (30.3) 158 700 (27.9) 
Renal disease 7 039 (9.2) 3 644 (8.5) 40 703 (7.2) 
End-stage renal disease 974 (1.3) 778 (1.8) 8 866 (1.6) 
Liver disease 2 489 (3.2) 2 398 (5.6) 15 306 (2.7) 
Dementia 9 755 (12.7) 1 226 (2.9) 35 086 (6.2) 
Cancer 21 387 (27.9) 7 110 (16.6) 106 704 (18.8) 
Metastatic cancer 5 178 (6.7) 903 (2.1) 18 613 (3.3) 
Peptic ulcer disease 6 101 (7.9) 3 209 (7.5) 32 653 (5.7) 
Rheumatoid arthritis or connective tissue disease 4 173 (5.4) 2 260 (5.3) 32 740 (5.8) 
Co-medication (prescription within 90 days) 
Total number of antihypertensive drugs 
  0 39 555 (51.5) 22 989 (53.7) 322 012 (56.7) 
  1 21 680 (28.2) 9 923 (23.2) 130 685 (23.0) 
  2 11 318 (14.7) 6 659 (15.5) 81 190 (14.3) 
  3 3 523 (4.6) 2 582 (6.0) 27 956 (4.9) 
  4 648 (0.8) 631 (1.5) 5 832 (1.0) 
  5 38 (0.0) 43 (0.1) 344 (0.1) 
ACE-I 11 915 (15.5) 7 239 (16.9) 82 358 (14.5) 
ARB 6 342 (8.3) 4 189 (9.8) 53 255 (9.4) 
CCB 10 093 (13.1) 6 553 (15.3) 71 116 (12.5) 
Thiazides 11 343 (14.8) 6 265 (14.6) 79 879 (14.1) 
Beta-blockers 17 332 (22.6) 9 050 (21.1) 111 315 (19.6) 
Other antihypertensive drugs 882 (1.1) 633 (1.5) 6 238 (1.1) 
Statins 13 882 (18.1) 9 271 (21.6) 112 995 (19.9) 
Aspirin 20 813 (27.1) 9 308 (21.7) 120 295 (21.2) 
Loop diuretics 26 763 (34.9) 10 768 (25.1) 127 995 (22.5) 
Immunosuppressants 716 (0.9) 555 (1.3) 6 744 (1.2) 
Glucocorticoids 13 864 (18.1) 5 765 (13.5) 78 980 (13.9) 
NSAID 9 173 (11.9) 5 957 (13.9) 68 602 (12.1) 
Opioids 28 517 (37.1) 10 859 (25.4) 144 942 (25.5) 
Vitamin K antagonists 5 315 (6.9) 3 044 (7.1) 38 277 (6.7) 
Proton pump inhibitors 25 845 (33.7) 10 954 (25.6) 147 542 (26.0) 
Antidepressants 21 494 (28.0) 9 481 (22.1) 121 248 (21.3) 
Hypnotics/sedatives 13 963 (18.2) 6 336 (14.8) 79 343 (14.0) 
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Death within 30 
days ICU admission 
Overall study 
population 
Antipsychotics 7 673 (10.0) 3 725 (8.7) 39 434 (6.9) 
Antibiotics (prescription within 10 days) 18 201 (23.7) 7 442 (17.4) 160 059 (28.2) 
Antivirals (prescription within 10 days) 142 (0.2) 68 (0.2) 1 537 (0.3) 
Lifestyle and social factors 
Markers of smoking 34 551 (45.0) 21 621 (50.5) 279 883 (49.3) 
Obesity 3 622 (4.7) 3 908 (9.1) 44 194 (7.8) 
Alcoholism 6 551 (8.5) 7 002 (16.3) 46 063 (8.1) 
Marital status 
  Widow 30 732 (40.0) 9 352 (21.8) 153 071 (26.9) 
  Divorced 10 552 (13.7) 7 780 (18.2) 85 766 (15.1) 
  Married 28 207 (36.7) 18 398 (43.0) 245 727 (43.3) 
  Unmarried 7 271 (9.5) 7 297 (17.0) 83 455 (14.7) 
Urban residence 26 494 (34.5) 13 268 (31.0) 208 285 (36.7) 
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Figure S1. Study design. 
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